# 4D Molecular Therapeutics, Inc. > Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero. ## Record | Field | Value | | --- | --- | | Representation | alpha-profile-markdown-v4 | | Protocol | Alpha Governance Facts Protocol 0.1 | | Schema | alpha.governance.entity.public.v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | Governance record representation | alpha-governance-record-v2 | | Canonical entity | alpha:company:61446dd8-308b-4fdb-9a36-eea449c21054 | | Entity type | Company | | Canonical URL | https://registry.alpha.ac/companies/4d-molecular-therapeutics-inc | | Publication | PUBLISHED | | Verification | source_reported | | Verification schema | alpha-verification-states-v1 | | Ownership | unclaimed | | Published claims | 19 | | Claims under review | 1 | | Evidence records | 5 | | Conflicts | 0 | | Conflicts in internal review | 0 | | Observed | 2026-10-15T04:46:11.014891+00:00 | | Last reviewed | 2026-10-15T04:46:11.014891+00:00 | ## Identity - Legal name: 4D Molecular Therapeutics, Inc. - Display name: 4D Molecular Therapeutics, Inc. ## Alpha Governance Record | Field | Value | | --- | --- | | Governance Record schema | alpha-governance-record-v2 | | Ontology | alpha-governance-ontology-v1 | | Record version | public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce | | As of | 2026-10-15T21:11:18.319385+00:00 | | Completeness | 0.409 | | Record Quality | 0.831 | | Directors | 9 | | Committees | 1 | | Governance events | 8 | | Entity class | public_company | ## Section coverage | Section | State | | --- | --- | | identity | PUBLISHED | | corporate_structure | NOT_REVIEWED | | board | PUBLISHED | | committees | PUBLISHED | | leadership | PUBLISHED | | ownership | NOT_REVIEWED | | financials | NOT_REVIEWED | | capital_structure | PUBLISHED | | compensation | NOT_REVIEWED | | governance | NOT_REVIEWED | | shareholder_governance | NOT_REVIEWED | | audit | NOT_REVIEWED | | legal | NOT_REVIEWED | | risk | NOT_REVIEWED | | cyber | NOT_REVIEWED | | ai_governance | NOT_REVIEWED | | agent_governance | RESTRICTED | | markets_external | NOT_REVIEWED | | events | PUBLISHED | | relationships | PUBLISHED | | assessments | PUBLISHED | | evidence | PUBLISHED | ## Board - Charles Theuer: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2015-01-01. claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:6 - David Kirn, M.D.: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2013-01-01. claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:8 - Glenn Sblendorio: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2026-01-01. claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:9 - Nancy Miller-Rich: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2020-01-01. claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:11 - Shawn Cline Tomasello: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2020-01-01. claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:12 - Susannah Gray: Director. Status: current. Independent: NOT_PUBLISHED. Since: 2020-01-01. claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:13 - David Kirn: Director, President and Chief Executive Officer. Status: unknown. Independent: false. Since: NOT_PUBLISHED. Committees: President and Chief Executive Officer (member). claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:7 - Jacob Chacko: Director. Status: unknown. Independent: true. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:10 - John F. Milligan: Director and Executive Chairman. Status: unknown. Independent: false. Since: NOT_PUBLISHED. claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:5 ## Committees - President and Chief Executive Officer (executive). Chair: NOT_PUBLISHED. Members: David Kirn (member, unknown). committee_id=alpha:committee:4d-molecular-therapeutics-inc:president-and-chief-executive-officer ## Executive leadership - David Kirn, M.D.: President, Chief Executive Officer and Director [CEO]. Status: current. claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:16 - Scott Bizily, J.D., Ph.D.: Chief Legal Officer and Corporate Secretary [GC]. Status: current. claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:19 - Christopher Simms: Chief Commercial and Business Officer. Status: unknown. claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:14 - David Kirn: President and Chief Executive Officer [CEO]. Status: unknown. claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:15 - Kristian Humer: Chief Financial Officer [CFO]. Status: unknown. claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:17 - Scott Bizily: Chief Legal Officer and Corporate Secretary [GC]. Status: unknown. claim_id=alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:18 ## Governance events - CEO_CHANGED: David Kirn, M.D. executive of 4D Molecular Therapeutics, Inc., effective 2026-04-28. Effective: 2026-04-28. Detected: 2026-10-15T04:46:11.014891+00:00. event_id=alpha:event:transition:hfqibt175j0an - GC_CHANGED: Scott Bizily, J.D., Ph.D. executive of 4D Molecular Therapeutics, Inc., effective 2026-04-28. Effective: 2026-04-28. Detected: 2026-10-15T04:46:11.014891+00:00. event_id=alpha:event:transition:s1cxnb1e8fgo1 - DIRECTOR_APPOINTED: Glenn Sblendorio seat on 4D Molecular Therapeutics, Inc., effective 2026-01-01. Effective: 2026-01-01. Detected: 2026-10-15T04:46:11.014891+00:00. event_id=alpha:event:transition:op4xfm1apmuug - DIRECTOR_APPOINTED: Nancy Miller-Rich seat on 4D Molecular Therapeutics, Inc., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-15T04:46:11.014891+00:00. event_id=alpha:event:transition:1tew30vvhfey3 - DIRECTOR_APPOINTED: Shawn Cline Tomasello seat on 4D Molecular Therapeutics, Inc., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-15T04:46:11.014891+00:00. event_id=alpha:event:transition:1aidwre1cdmros - DIRECTOR_APPOINTED: Susannah Gray seat on 4D Molecular Therapeutics, Inc., effective 2020-01-01. Effective: 2020-01-01. Detected: 2026-10-15T04:46:11.014891+00:00. event_id=alpha:event:transition:1netptt141etep - DIRECTOR_APPOINTED: Charles Theuer seat on 4D Molecular Therapeutics, Inc., effective 2015-01-01. Effective: 2015-01-01. Detected: 2026-10-15T04:46:11.014891+00:00. event_id=alpha:event:transition:1c37mix15gqgvr - DIRECTOR_APPOINTED: David Kirn, M.D. seat on 4D Molecular Therapeutics, Inc., effective 2013-01-01. Effective: 2013-01-01. Detected: 2026-10-15T04:46:11.014891+00:00. event_id=alpha:event:transition:fnatsr1815lzv ## Scoped resources - `alpha://company/4d-molecular-therapeutics-inc` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record - `alpha://company/4d-molecular-therapeutics-inc/identity` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=identity - `alpha://company/4d-molecular-therapeutics-inc/corporate-structure` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=corporate-structure - `alpha://company/4d-molecular-therapeutics-inc/board` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=board - `alpha://company/4d-molecular-therapeutics-inc/committees` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=committees - `alpha://company/4d-molecular-therapeutics-inc/leadership` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=leadership - `alpha://company/4d-molecular-therapeutics-inc/ownership` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=ownership - `alpha://company/4d-molecular-therapeutics-inc/financials` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=financials - `alpha://company/4d-molecular-therapeutics-inc/capital-structure` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=capital-structure - `alpha://company/4d-molecular-therapeutics-inc/compensation` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=compensation - `alpha://company/4d-molecular-therapeutics-inc/governance` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=governance - `alpha://company/4d-molecular-therapeutics-inc/shareholder-governance` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=shareholder-governance - `alpha://company/4d-molecular-therapeutics-inc/audit` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=audit - `alpha://company/4d-molecular-therapeutics-inc/legal` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=legal - `alpha://company/4d-molecular-therapeutics-inc/risk` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=risk - `alpha://company/4d-molecular-therapeutics-inc/cyber` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=cyber - `alpha://company/4d-molecular-therapeutics-inc/ai-governance` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=ai-governance - `alpha://company/4d-molecular-therapeutics-inc/agents` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=agents - `alpha://company/4d-molecular-therapeutics-inc/ecosystem` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=ecosystem - `alpha://company/4d-molecular-therapeutics-inc/events` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=events - `alpha://company/4d-molecular-therapeutics-inc/relationships` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=relationships - `alpha://company/4d-molecular-therapeutics-inc/assessments` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=assessments - `alpha://company/4d-molecular-therapeutics-inc/evidence` (contract): https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record§ion=evidence ## Role modules - NOT_ASSERTED ## Attention - NO_RECORDS_FOUND ## Committee data - NO_RECORDS_FOUND ## Leadership - John F. Milligan: Director and Executive Chairman. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:5. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:d6c21ef372431bf542d94718760db06ff345eb4b51cc166e17d5cd9db2663710. - Charles Theuer: Director. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:6. Valid from: 2015-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:95e44af3aa0f2000d482bf79d42ab1f36f1ce83e68de4fd69428c585de6c6f0a. - David Kirn: Director, President and Chief Executive Officer. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:7. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:d6c21ef372431bf542d94718760db06ff345eb4b51cc166e17d5cd9db2663710. - David Kirn, M.D.: Director. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:8. Valid from: 2013-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:95e44af3aa0f2000d482bf79d42ab1f36f1ce83e68de4fd69428c585de6c6f0a. - Glenn Sblendorio: Director. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:9. Valid from: 2026-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:95e44af3aa0f2000d482bf79d42ab1f36f1ce83e68de4fd69428c585de6c6f0a. - Jacob Chacko: Director. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:10. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:d6c21ef372431bf542d94718760db06ff345eb4b51cc166e17d5cd9db2663710. - Nancy Miller-Rich: Director. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:11. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:95e44af3aa0f2000d482bf79d42ab1f36f1ce83e68de4fd69428c585de6c6f0a. - Shawn Cline Tomasello: Director. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:12. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:95e44af3aa0f2000d482bf79d42ab1f36f1ce83e68de4fd69428c585de6c6f0a. - Susannah Gray: Director. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:13. Valid from: 2020-01-01. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:95e44af3aa0f2000d482bf79d42ab1f36f1ce83e68de4fd69428c585de6c6f0a. - Christopher Simms: Chief Commercial and Business Officer. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:14. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:d6c21ef372431bf542d94718760db06ff345eb4b51cc166e17d5cd9db2663710. - David Kirn: President and Chief Executive Officer. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:15. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:d6c21ef372431bf542d94718760db06ff345eb4b51cc166e17d5cd9db2663710. - David Kirn, M.D.: President, Chief Executive Officer and Director. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:16. Valid from: 2026-04-28. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:ce30a281ead5bce2f489fc14c959316ac3d01718e2cd67c6bd59b77accad6371. - Kristian Humer: Chief Financial Officer. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:17. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:d6c21ef372431bf542d94718760db06ff345eb4b51cc166e17d5cd9db2663710. - Scott Bizily: Chief Legal Officer and Corporate Secretary. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:18. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:d6c21ef372431bf542d94718760db06ff345eb4b51cc166e17d5cd9db2663710. - Scott Bizily, J.D., Ph.D.: Chief Legal Officer and Corporate Secretary. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:leadership_role:19. Valid from: 2026-04-28. Valid to: NOT_ASSERTED. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:document:cab7c27c3983e81d7121841a507d1fb330aed80845e1ac0f5f6a2ba647a1c34a. ## Roles - PUBLISHED ## Governance - NOT_ASSERTED ## Board committees - PUBLISHED ## Financials - NOT_ASSERTED ## Workforce - NOT_ASSERTED ## Market and index context - PUBLISHED ## Legal Name - 4D Molecular Therapeutics, Inc.. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:legal_name:1. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:ec8896ef0fa3cb8ec4fa8eb8e3ae0199730bbddd9e856f3842d402756552ac84. ## Entity Status - Public listing published. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:entity_status:3. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:ec8896ef0fa3cb8ec4fa8eb8e3ae0199730bbddd9e856f3842d402756552ac84. ## Published Fact - US. Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:published_fact:4. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:ec8896ef0fa3cb8ec4fa8eb8e3ae0199730bbddd9e856f3842d402756552ac84. ## Security Listing - FDMT (NASDAQ). Claim: alpha:claim:company:61446dd8-308b-4fdb-9a36-eea449c21054:security_listing:20. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:projection-evidence:ec8896ef0fa3cb8ec4fa8eb8e3ae0199730bbddd9e856f3842d402756552ac84. ## Coverage states | Field | Value | | --- | --- | | Identity | PUBLISHED | | Business | PUBLISHED | | Leadership | PUBLISHED | | Board and committees | PUBLISHED | | Governance | NOT_ASSERTED | | Financials | NOT_ASSERTED | | Workforce | NOT_ASSERTED | | Ownership | NOT_ASSERTED | | Ratings | NOT_PUBLISHED | | Market and index context | PUBLISHED | ## Public sources - alpha:projection-evidence:ec8896ef0fa3cb8ec4fa8eb8e3ae0199730bbddd9e856f3842d402756552ac84: [Alpha canonical company public projection](https://www.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc). - alpha:projection-evidence:document:d6c21ef372431bf542d94718760db06ff345eb4b51cc166e17d5cd9db2663710: [SEC DEF 14A 0001140361-26-017427](https://www.sec.gov/Archives/edgar/data/1650648/000114036126017427/ny20063669x1_def14a.htm). - alpha:projection-evidence:document:95e44af3aa0f2000d482bf79d42ab1f36f1ce83e68de4fd69428c585de6c6f0a: [DEF 14A ny20063669x1_def14a.htm](https://www.sec.gov/Archives/edgar/data/1650648/000114036126017427/ny20063669x1_def14a.htm). - alpha:projection-evidence:document:ce30a281ead5bce2f489fc14c959316ac3d01718e2cd67c6bd59b77accad6371: [FDMT DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1650648/000114036126017427/ny20063669x1_def14a.htm). - alpha:projection-evidence:document:cab7c27c3983e81d7121841a507d1fb330aed80845e1ac0f5f6a2ba647a1c34a: [FDMT DEF 14A executive officers](https://www.sec.gov/Archives/edgar/data/1650648/000114036126017427/ny20063669x1_def14a.htm). ## Rights | Field | Value | | --- | --- | | public_retrieval | allowed | | agent_retrieval | allowed | | redistribution | not_granted | | model_training | not_granted | | commercial_use | not_specified | | relationship_pathfinding | not_granted | | direct_contact | not_granted | ## Limitations - Absence of a leadership role, committee, or disclosure is not evidence that it does not exist. - Only explicitly published canonical company identity and current confirmed public roles are included. - Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist. - Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights. - This Company Profile is an identity and evidence record, not an Alpha rating. ## Alternate representations - [Canonical profile](https://registry.alpha.ac/companies/4d-molecular-therapeutics-inc) - [Public Markdown](https://registry.alpha.ac/companies/4d-molecular-therapeutics-inc.md) - [Public JSON](https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=record) - [JSON-LD](https://registry.alpha.ac/api/public/companies/4d-molecular-therapeutics-inc?format=jsonld) - MCP resource: `alpha://companies/4d-molecular-therapeutics-inc` at https://mcp.alpha.ac/mcp ## Connected governance records Only explicitly published, rights-cleared records. Missing records do not establish absence, safety, or complete coverage. ## Critical-risk oversight Snapshot as of 2026-10-15T21:11:18.127987+00:00; recorded 2026-10-15T21:11:18.127987+00:00. Every published assignment for this snapshot is listed. Only explicitly reviewed, rights-cleared assignments in effect on the as-of date, in the company's own wording. An assignment shows where oversight is placed, not whether it is effective. Missing records do not establish absence.